PlainPharmaWatch

CMS Open Payments · Program Year 2024

Immunitybio, Inc.

Immunitybio, Inc. reported $67,816.03 across General Payments, Research, and Ownership to 1,612 physicians and teaching hospitals across 1,612 transactions.

See the rankings → How this is sourced
$67.8K
All-tracks total
1,612
Transactions
1,612
Recipients
#1276
of 1,925 companies

Immunitybio, Inc. reported $67,816.03 across all CMS Open Payments tracks (General + Research + Ownership) to 1,612 physicians and teaching hospitals in Program Year 2024 - ranking #1276 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $67,816.03, averaging $42.07 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

Compiled from official public sources by the publisher.

CMS Sunshine Act warrant

Manufacturer immunitybio-inc Immunitybio, Inc.

$67.8K · #1276/1,925 · 0.0% industry · PY2024

  • TOT $67.8K
  • RANK #1276
  • SHARE 0.0%
  • TXN 1,612
  • RCP 1,612
  • CAT 3
  • GEN $67.8K
  • TOP1 5.7%
  • PY 2024

Volume peers

Nearest volume peer: Shimadzu Precision Instruments, Inc. ($67.9K)

RedHill Biopharma Inc.$68.8KShimadzu Precision Instrumen…$67.9KImmunitybio, Inc. (this)$67.8KMIM Software Inc.$67.1KIcometrix NV$67.0K
All-tracks payment totals near Immunitybio, Inc. (CMS Open Payments PY2024)

Immunitybio, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

What the Data Shows for Immunitybio, Inc.

Immunitybio, Inc. ranks #1276 out of 1,925 companies in the CMS Open Payments database for Program Year 2024, a comparatively small 0.0% slice of all industry payments reported nationwide for the year. The underlying total is $67,816.03 across 1,612 transactions to 1,612 physicians and teaching hospitals - $42.07 per transaction and $42.07 per recipient on average.

The 3-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Food and Beverage" at $44.0K, accounting for 64.9% of this company's General Payments and 1,599 transactions.

General Payment Breakdown by Type

Immunitybio, Inc. made 3 types of general payments. "Food and Beverage" is the largest category at $44.0K, 64.9% of General Payments.

How Immunitybio, Inc. divides its payments

Top payment categories by total reported dollar volume

1. Food and Beverage$44.0K2. Honoraria$17.6K3. Consulting Fee$6.2K
Payment Type Amount Transactions
Food and Beverage $44.0K 1,599
Honoraria $17.6K 11
Consulting Fee $6.2K 2

Recipient Concentration in General Payments

The five largest recipient relationships account for $13,187.01 (19.4%) of $67,816.03 in this company's General Payments records across 1,282 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Immunitybio, Inc.

The five named recipients with the highest reported General Payments from this company

Jason Matthew Hafron$3.9KGary Steinberg$2.4KPeter O Donnell$2.4KJoshua Meeks$2.4KArpeet Satish Shah$2.1K
  1. 1

    Jason Matthew Hafron

    $3,864.40 across 5 reported transactions

  2. 2

    Gary Steinberg

    $2,400.00 across 1 reported transactions

  3. 3

    Peter O Donnell

    $2,400.00 across 1 reported transactions

  4. 4

    Joshua Meeks

    $2,400.00 across 1 reported transactions

  5. 5

    Arpeet Satish Shah

    $2,122.61 across 2 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Immunitybio, Inc.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Immunitybio, Inc..

Metacel Pharmaceuticals LLC

HHI 123

Geistlich Pharma, North America, Inc.

HHI 122

Foundation Medical, Llc

HHI 123

Esperion Therapeutics, Inc.

HHI 121

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Immunitybio, Inc..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. Total industry payments: $13.9B across 1,925 companies.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

View saved (companies)
Download Immunitybio, Inc.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.